List of Peptide Therapies Companies in Japan - 10

A public biopharmaceutical company focused on developing novel cancer immunotherapies.

EA Pharma Co., Ltd. is a pharmaceutical company that promotes drug discovery and clinical development targeting gastrointestinal diseases, particularly Inflammatory Bowel Disease (IBD). The company is focused on creating new innovation through the combined knowledge of its parent companies, Eisai Co., Ltd. and Ajinomoto Co., Inc.

Epsilon Molecular Engineering (EME) Inc. is an evolutionary molecular engineering based biopharmaceutical drug discovery company. EME was established in 2016 as a venture company from Saitama University in Japan, and has proprietary technologies, unique cDNA display libraries of the heavy chain single domain antibodies (VHH) and cyclic peptides with large diversity (10^13-14), and high-throughput screening methods using next-generation sequence, FACS and Machine learning (Bioinformatics). EME is, currently, conducting several joint research projects, including COVID-19, and 17 ongoing inhouse projects in the arias of cancer, inflammation, and Alzheimer’s disease, etc.

Kissei Pharmaceutical - Approaching R&D with Passion and Creativity “Pharmaceutical company cannot exist without R&D.” These words have been passed down at Kissei ever since the company was founded. They show that R&D is an essential and central part of our work, The phrase also expresses the passion of each and every Kissei Pharmaceutical - Kissei employee for the development of new innovative drugs, in the hope that those drugs will help as many people as possible recover as quickly as possible from disease and live lives full of laughter and joy. We aim to develop and supply innovative pharmaceutical products that contribute to the improvement of medicine and the health of people around the world by aggressive incorporation of leading-edge technology and collaborations with our foreign and domestic partners.

Luxna Biotech is a preclinical antisense drug development company based on proprietary modified nucleic acids, unique bridged structure (AmNA, scpBNA, GuNA) and modified DNA (5'-CP) can eliminate phosphorothioated in antisense and siRNA. Currently, better modifications are being discovered that are suitable for applications in neurological diseases that minimize neurotoxicity while maintaining knockdown efficacy in vivo by Gapmer. Based on these findings we developed excellent antisense (ASO) drug discovery platform called “LuxiAPTM” enable to wide therapeutic index for CNS ASO drug. We have several pharmaceutical collaborations and original ASO pipeline including ALS, Spinal cord injury and Hearing loss. We are looking for the partners not only for platform collaboration with pharmaceuticals and biotech but early-stage co-development alliance with our original pipeline.

OncoTherapy Science, Inc. provides pharmaceutical companies with yielded drug candidates by using outcomes obtained from joint research with universities and companies. These outcomes include oncogene information isolated by comprehensive analysis of genes specifically expressed in cancer cells and functional analysis information of proteins produced by oncogenes and other gene products. We have also been performing research and development business regarding medications.

PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. Founded in 2006, PeptiDream employs its proprietary Peptide Discovery Platform System (PDPS) technology, a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate (PDC), and multi-functional peptide conjugates (MPC)-based therapeutics and diagnostics. PeptiDream has an extensive global network of discovery and development partners driving the development and commercialization of a broad and diversified pipeline of investigational therapeutics. PeptiDream also markets and sells a number of radiopharmaceutical and radiodiagnostic products in Japan, through its wholly owned subsidiary, PDRadiopharma.

RaQualia Pharma - We are an innovative pharmaceutical company leveraging our expertise in drug discovery research and our collaborations with state-of-the-art academic research institutions.

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. It develops drugs in the areas of pain, heart failure, and other diseases. The company has 25 employees as of March 2023 and is headquartered in Minato, Tokyo.

TAGCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.